Diabetic ketoacidosis (DKA) is a severe complication of diabetes, primarily affecting individuals with type 1 diabetes (T1D). However, one-third of hospitalized cases involve type 2 diabetes (T2D). Although DKA typically presents with hyperglycemia (>250 mg/dL), the increased use of sodium-glucose transporter 2 inhibitors in addition to other conditions that can increase the risk of euglycemic DKA, or DKA with normal glucose levels, has been growing. DKA hospitalizations in the United States have risen significantly. From 2009 to 2014, hospitalization rates increased 54.9%. Despite a mortality rate of <2%, the growing prevalence of diabetes continues to drive DKA-related hospitalizations, posing a significant health and economic burden. This article examines the prevalence and economic impact of DKA among various diabetes populations in the United States.
KitabchiAE, UmpierrezGE, MilesJM, FisherJN. Hyperglycemic crises in adult patients with diabetes. Diabetes Care, 2009; 32(7):1335–1343; doi: 10.2337/dc09-903
2.
UmpierrezGE, DavisGM, ElSayedNA, et al.Hyperglycaemic crises in adults with diabetes: A consensus report. Diabetologia, 2024; 67(8):1455–1479; doi: 10.1007/s00125-024-06183-8
VellankiP, UmpierrezGE. Diabetic ketoacidosis risk during the COVID-19 pandemic. Lancet Diabetes Endocrinol, 2021; 9(10):643–644; doi: 10.1016/S2213-8587(21)00241-2
5.
LebovitzHE, BanerjiMA. Ketosis-prone diabetes (Flatbush diabetes): An emerging worldwide clinically important entity. Curr Diab Rep, 2018; 18(11):120; doi: 10.1007/s11892-018-1075-4
6.
McCoyRG, GalindoRJ, SwarnaKS, et al.Sociodemographic, clinical, and treatment-related factors associated with hyperglycemic crises among adults with type 1 or type 2 diabetes in the US from 2014 to 2020. JAMA Netw Open, 2021; 4(9):e2123471; doi: 10.1001/jamanetworkopen.2021.23471
MoraceC, LorelloG, BelloneF, et al.Ketoacidosis and SGLT2 inhibitors: A narrative review. Metabolites, 2024; 14(5):264; doi: 10.3390/metabo14050264
9.
BenoitSR, ZhangY, GeissLS, et al.Trends in diabetic ketoacidosis hospitalizations and in-hospital mortality—United States, 2000–2014. MMWR Morb Mortal Wkly Rep, 2018; 67(12):362–365.
10.
KichlooA, El-AmirZ, WaniF, ShakaH. Hospitalizations for ketoacidosis in type 1 diabetes mellitus, 2008 to 2018. Proc (Bayl Univ Med Cent), 2022; 35(1):1–5; doi: 10.1080/08998280.2021.1978741
11.
PasquelFJ, TsegkaK, WangH, et al.Clinical outcomes in patients with isolated or combined diabetic ketoacidosis and hyperosmolar hyperglycemic state: A retrospective, hospital-based cohort study. Diabetes Care, 2020; 43(2):349–357; doi: 10.2337/dc19-1168
12.
GoguenJ, GilbertJ, Diabetes Canada Clinical Practice Guidelines Expert Committee. Hyperglycemic Emergencies in Adults. Can J Diabetes, 2018; 42,(Suppl 1):S109–S114; doi: 10.1016/j.jcjd.2017.10.013
13.
ShandJAD, MorrowP, BraatvedtG. Mortality after discharge from hospital following an episode of diabetic ketoacidosis. Acta Diabetol, 2022; 59(11):1485–1492; doi: 10.1007/s00592-022-01953-5
14.
HammersenJ, TittelSR, WarnckeK, et al.; DPV Initiative. Previous diabetic ketoacidosis as a risk factor for recurrence in a large prospective contemporary pediatric cohort: Results from the DPV initiative. Pediatr Diabetes, 2021; 22(3):455–462; doi: 10.1111/pedi.13185
15.
Agency for Healthcare Research and Quality. Healthcare cost and utilization project: Overview of the National (nationwide) Inpatient Sample (NIS). Available from: https://hcup-us.ahrq.gov/nisoverview.jsp [Last accessed: April20, 2025].
16.
RamphulK, JoynauthJ. An update on the incidence and burden of diabetic ketoacidosis in the U.S. Diabetes Care, 2020; 43(12):e196–e197; doi: 10.2337/dc20-1258
17.
HurtadoCR, LemorA, VallejoF, et al.Causes and predictors for 30-day re-admissions in adult patients with diabetic ketoacidosis in the United States: A nationwide analysis, 2010-2014. Endocr Pract, 2019; 25(3):242–253; doi: 10.4158/EP-2018-0457
18.
MaldonadoMR, ChongER, OehlMA, BalasubramanyamA. Economic impact of diabetic ketoacidosis in a multiethnic indigent population: Analysis of costs based on the precipitating cause. Diabetes Care, 2003; 26(4):1265–1269; doi: 10.2337/diacare.26.4.1265
19.
VarugheseB, OliverL, LavelleP, et al.EPH179 the economic impact of diabetic ketoacidosis (DKA) in people with T1DM at high risk for DKA: A structured literature review. Value in Health, 2022; 25(12):S225; doi: 10.1016/j.jval.2022.09.1100
20.
SaydahSH, ShresthaSS, ZhangP, et al.Medical costs among youth younger than 20 years of age with and without diabetic ketoacidosis at the time of diabetes diagnosis. Diabetes Care, 2019; 42(12):2256–2261; doi: 10.2337/dc19-1041
21.
ShakaH, WaniF, El-AmirZ, et al.Comparing patient characteristics and outcomes in type 1 versus type 2 diabetes with diabetic ketoacidosis: A review and a propensity-matched nationwide analysis. J Investig Med, 2021; 69(6):1196–1200; doi: 10.1136/jim-2021-001901
22.
WyshamC, BindalA, Levrat-GuillenF, et al.A systematic literature review on the burden of diabetic ketoacidosis in type 2 diabetes mellitus. Diabetes Obes Metab, 2025; 27(5):2750–2767; doi: 10.1111/dom.16282
23.
JeyamA, GibbFW, McKnightJA, et al.; Scottish Diabetes Research Network (SDRN) Epidemiology Group. Marked improvements in glycaemic outcomes following insulin pump therapy initiation in people with type 1 diabetes: A nationwide observational study in Scotland. Diabetologia, 2021; 64(6):1320–1331; doi: 10.1007/s00125-021-05413-7
24.
BiesterT, SchwandtA, HeidtmannB, et al.; DPV Initiative. Declining frequency of acute complications associated with tubeless insulin pump use: Data from 2,911 patients in the German/Austrian Diabetes Patienten Verlaufsdokumentation Registry. Diabetes Technol Ther, 2021; 23(8):527–536; doi: 10.1089/dia.2020.0675
25.
GiessmannLC, KannPH. Risk and relevance of insulin pump therapy in the aetiology of ketoacidosis in people with type 1 diabetes. Exp Clin Endocrinol Diabetes, 2020; 128(11):745–751.
26.
WersällJH, AdolfssonP, ForsanderG, HanasR. Insulin pump therapy is associated with higher rates of mild diabetic ketoacidosis compared to injection therapy: A 2-year Swedish national survey of children and adolescents with type 1 diabetes. Pediatr Diabetes, 2022; 23(7):1038–1044; doi: 10.1111/pedi.13377
27.
FloresM, AmirM, AhmedR, et al.Causes of diabetic ketoacidosis among adults with type 1 diabetes mellitus: Insulin pump users and non-users. BMJ Open Diabetes Res Care, 2020; 8(2):e001329; doi: 10.1136/bmjdrc-2020-001329
28.
DhanasekaranM, MohanS, EricksonD, et al.Diabetic ketoacidosis in pregnancy: Clinical risk factors, presentation, and outcomes. J Clin Endocrinol Metab, 2022; 107(11):3137–3143; doi: 10.1210/clinem/dgac464
29.
KargesB, RosenbauerJ, Stahl-PeheA, et al.Hybrid closed-loop insulin therapy and risk of severe hypoglycaemia and diabetic ketoacidosis in young people (aged 2–20 years) with type 1 diabetes: A population-based study. Lancet Diabetes Endocrinol, 2025; 13(2):88–96; doi: 10.1016/S2213-8587(24)00284-5
30.
DanneT, GargS, PetersAL, et al.International consensus on risk management of diabetic ketoacidosis in patients with type 1 diabetes treated with Sodium–Glucose Cotransporter (SGLT) inhibitors. Diabetes Care, 2019; 42(6):1147–1154.
31.
KibbeyRG. SGLT-2 inhibition and glucagon: Cause for alarm? Trends Endocrinol Metab, 2015; 26(7):337–338.
32.
MillerKM, FosterNC, BeckRW, et al.; T1D Exchange Clinic Network. Current state of type 1 diabetes treatment in the U.S.: updated data from the T1D Exchange clinic registry. Diabetes Care, 2015; 38(6):971–978.
33.
DandonaP, MathieuC, PhillipM, et al.; DEPICT-1 Investigators. Efficacy and safety of dapagliflozin in patients with inadequately controlled type 1 diabetes (DEPICT-1): 24 week results from a multicentre, double-blind, phase 3, randomised controlled trial. Lancet Diabetes Endocrinol, 2017; 5(11):864–876.
34.
MathieuC, DandonaP, GillardP, et al.; DEPICT-2 Investigators. Efficacy and safety of dapagliflozin in patients with inadequately controlled type 1 diabetes (the DEPICT-2 study): 24-week results from a randomized controlled trial. Diabetes Care, 2018; 41(9):1938–1946.
35.
GargSK, HenryRR, BanksP, et al.Effects of sotagliflozin added to insulin in patients with type 1 diabetes. N Engl J Med, 2017; 377(24):2337–2348.
36.
SandsAT, ZambrowiczBP, RosenstockJ, et al.Sotagliflozin, a dual SGLT1 and SGLT2 inhibitor, as adjunct therapy to insulin in type 1 diabetes. Diabetes Care, 2015; 38(7):1181–1188.
37.
HenryRR, ThakkarP, TongC, et al.Efficacy and safety of canagliflozin, a sodium-glucose cotransporter 2 inhibitor, as add-on to insulin in patients with type 1 diabetes. Diabetes Care, 2015; 38(12):2258–2265.
38.
EronduN, DesaiM, WaysK, MeiningerG. Diabetic ketoacidosis and related events in the canagliflozin type 2 diabetes clinical program. Diabetes Care, 2015; 38(9):1680–1686.
39.
PlewaMC, BryantM, King-ThieleR. Euglycemic Diabetic Ketoacidosis. In: StatPearls. Treasure Island (FL): StatPearls Publishing; 2022. Available from: https://www.ncbi.nlm.nih.gov/books/NBK554570/
CatalanoPM, TyzbirED, RomanNM, et al.Longitudinal changes in insulin release and insulin resistance in nonobese pregnant women. Am J Obstet Gynecol, 1991; 165(6 Pt 1):1667–1672; doi: 10.1016/0002-9378(91)90012-g
42.
MorrisonFJR, MovassaghianM, SeelyEW, et al.Fetal outcomes after diabetic ketoacidosis during pregnancy. Diabetes Care, 2017; 40(7):e77–e79; doi: 10.2337/dc17-0186
43.
MetzgerBE, RavnikarV, VileisisRA, FreinkelN. “Accelerated starvation” and the skipped breakfast in late normal pregnancy. Lancet, 1982; 1(8272):588–592; doi: 10.1016/s0140-6736(82)91750-0
44.
American College of Obstetricians and Gynecologists’ Committee on Practice Bulletins-Obstetrics. ACOG practice bulletin No. 201: Pregestational diabetes mellitus. Obstet Gynecol, 2018; 132(6):e228–e248; doi: 10.1097/AOG.0000000000002960
LyerlaR, Johnson-RabbettB, ShakallyA, et al.Recurrent DKA results in high societal costs - a retrospective study identifying social predictors of recurrence for potential future intervention. Clin Diabetes Endocrinol, 2021; 7(1):13; doi: 10.1186/s40842-021-00127-6
48.
Agency for Healthcare Research and Quality. Healthcare utilization project: Overview of the Nationwide readmissions database (NRD). Available from: https://hcup-us.ahrq.gov/nrdoverview.jsp [Last accessed: April23, 2025].
49.
ShakaH, AguileraM, AucarM, et al.Rate and predictors of 30-day readmission following diabetic ketoacidosis in type 1 diabetes mellitus: A US analysis. J Clin Endocrinol Metab, 2021; 106(9):2592–2599; doi: 10.1210/clinem/dgab372
50.
MaysJA, JacksonKL, DerbyTA, et al.An evaluation of recurrent diabetic ketoacidosis, fragmentation of care, and mortality across Chicago, Illinois. Diabetes Care, 2016; 39(10):1671–1676; doi: 10.2337/dc16-0668
51.
CooperH, TekitekiA, KhanolkarM, BraatvedtG. Risk factors for recurrent admissions with diabetic ketoacidosis: A case-control observational study. Diabet Med, 2016; 33(4):523–528; doi: 10.1111/dme.13004
52.
GarrettCJ, MoultonCD, ChoudharyP, et al.The psychopathology of recurrent diabetic ketoacidosis: A case-control study. Diabet Med, 2021; 38(7):e14505; doi: 10.1111/dme.14505
53.
PetitJM, GoueslardK, Chauvet-GelinierJC, et al.Association between hospital admission for ketoacidosis and subsequent suicide attempt in young adults with type 1 diabetes. Diabetologia, 2020; 63(9):1745–1752; doi: 10.1007/s00125-020-05206-4
54.
RobertsSE, GoldacreMJ, NeilHA. Mortality in young people admitted to hospital for diabetes: Database study. BMJ, 2004; 328(7442):741–742; doi: 10.1136/bmj.328.7442.741
55.
PolonskyWH, AndersonBJ, LohrerPA, et al.Insulin omission in women with IDDM. Diabetes Care, 1994; 17(10):1178–1185; doi: 10.2337/diacare.17.10.1178
56.
RydallAC, RodinGM, OlmstedMP, et al.Disordered eating behavior and microvascular complications in young women with insulin-dependent diabetes mellitus. N Engl J Med, 1997; 336(26):1849–1854; doi: 10.1056/NEJM199706263362601
57.
ShulmanR, LuoJ, ShahBR. Mental health visits and low socio-economic status in adolescence are associated with complications of Type 1 diabetes in early adulthood: A population-based cohort study. Diabet Med, 2018; 35(7):920–928; doi: 10.1111/dme.13633
58.
EverettE, MathioudakisNN. Association of socioeconomic status and DKA readmission in adults with type 1 diabetes: Analysis of the US National Readmission Database. BMJ Open Diabetes Res Care, 2019; 7(1):e000621; doi: 10.1136/bmjdrc-2018-000621
59.
Sheikh-AliM, KaronBS, BasuA, et al.Can serum beta-hydroxybutyrate be used to diagnose diabetic ketoacidosis? Diabetes Care, 2008; 31(4):643–647; doi: 10.2337/dc07-1683
60.
AlvaS, CastorinoK, ChoH, OuJ. Feasibility of continuous ketone monitoring in subcutaneous tissue using a ketone sensor. J Diabetes Sci Technol, 2021; 15(4):768–774; doi: 10.1177/19322968211008185
61.
Albanese-O’NeillA, WuM, MillerKM, et al.; T1D Exchange Clinic Network. Poor adherence to ketone testing in patients with type 1 diabetes. Diabetes Care, 2017; 40(4):e38–e39; doi: 10.2337/dc16-2620
62.
EL-MohandesN, YeeG, BhuttaBS, et al.Pediatric diabetic ketoacidosis. [Updated 2023 Aug 21]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025. Available from: https://www.ncbi.nlm.nih.gov/books/NBK470282/# [Last accessed: March18, 2025].
63.
PhelanH, HanasR, HoferSE, et al.Sick day management in children and adolescents with diabetes. Pediatr Diabetes, 2022; 23(7):912–925; doi: 10.1111/pedi.13415
64.
KargesB, TittelSR, BeyA, et al.Continuous glucose monitoring versus blood glucose monitoring for risk of severe hypoglycaemia and diabetic ketoacidosis in children, adolescents, and young adults with type 1 diabetes: A population-based study. Lancet Diabetes Endocrinol, 2023; 11(5):314–323; doi: 10.1016/S2213-8587(23)00061-X
65.
RivelineJP, RousselR, VicautE, et al.Reduced rate of acute diabetes events with flash glucose monitoring is sustained for 2 years after initiation: Extended outcomes from the RELIEF study. Diabetes Technol Ther, 2022; 24(9):611–618; doi: 10.1089/dia.2022.0085
